Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole
about
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference centerNew pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant EnterococciNationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetationsPharmacotherapeutic options for treating Staphylococcus aureus bacteremia.
P2860
Q34478074-A13946E3-0859-462E-BF35-0764A7A48A89Q35169018-134EF37F-640D-4930-9D51-959273584922Q35848781-7E7A5D17-A8AB-4DCD-92BE-7A857AA9B776Q35926840-AC7E3584-59D2-4A28-8782-40FBC3EF60D5Q38179460-3F17D26F-843F-47C4-AAE8-EAC992B652F2Q38425879-05D5DD7C-663E-4FC9-990E-87AEB73F039FQ38632488-06FBF805-065E-4F0D-BDFF-2D6DB887F596Q39516822-7BCF3402-71FC-4B96-A09B-EACC9386413FQ40243934-19D7B251-5F1C-4B7B-B764-EDAB9B31273DQ41074267-DF31A67E-C161-4681-8C0C-E9A7A1EAD1B1Q47634145-436C9597-4968-4CBE-8CD4-CB2CA4FA7059
P2860
Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@ast
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@en
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@nl
type
label
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@ast
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@en
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@nl
prefLabel
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@ast
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@en
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@nl
P2093
P2860
P356
P1476
Daptomycin-nonsusceptible vanc ...... trimethoprim-sulfamethoxazole
@en
P2093
Ashley E Woodruff
Lisa M Avery
Michael J Rybak
Molly E Steed
Muhammad Hasan
P2860
P304
P356
10.1128/AAC.01046-12
P407
P577
2012-11-01T00:00:00Z